GLP-1 works on multiple fronts: it enhances insulin secretion, inhibits glucagon production (reducing blood sugar), and delays gastric emptying, which leads to increased feelings of fullness (satiety)
The LEADER and SUSTAIN-6 trials, which followed diabetic patients for 37 years on GLP-1 therapy, documented reduced heart attacks and strokes without accumulation of serious toxicity
Often, the lyophilization process creates a small "puck" or disc at the bottom of the vial
Gastrointestinal complications alleged in GLP-1 litigation include: These allegations can overlap with other health conditions, including high blood pressure and other comorbidities that may complicate diagnosis and causation analysis
People with inflammatory skin conditions such as acne, rosacea, or eczema looking to reduce redness and inflammation
Studies have documented effects on chondrocyte function, cartilage matrix production, and joint inflammation markers, broadening AOD 9604s research applicability beyond its original metabolic focus